New Delhi, Dec. 12 -- Novo Nordisk on Friday launched Ozempic(R) (injectable semaglutide) in India. Ozempic(R) is a once-weekly GLP-1 RA (receptor agonist) indicated as an adjunct to diet and exercise for adults living with uncontrolled type 2 diabetes mellitus (T2DM). The cost of the medicine is Rs 2200 per dose.

Speaking about the injectable Ozempic Diabetes 2 weight loss drug, the Managing Director of Novo Nordisk, India, Vikrant Shrotriya, told ANI, "It is for type 2 diabetes. Many diabetes patients in India would require this medication as they also struggle with excess weight... We are also very sensitive to the Indian socioeconomic class, as we have introduced this medicine at Rs 2,200 per week."

"I believe that with this kind of...